Medicxi
Venture capital
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
7Deep-tech portfolio2 active
5Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: Nuvation Bio
27Co-investorsShare a portfolio company
Portfolio · 7 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| D3 Bio | Biotech | Active | — | — |
| Ottimo Pharma | Biotech | Active | — | — |
| Nuvation Bio | Biotech | Public | Oct 20, 2020 | $275.3M |
| Cardior Pharmaceuticals | Biotech | Acquired | — | — |
| Centessa Pharmaceuticals | Biotech | Acquired | — | — |
| Merus | Biotech | Acquired | — | — |
| ViceBio | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#60
Portfolio exits#40
Raises, 12 months#88
Co-investors#73
Co-investors
- Avoro Capital AdvisorsVenture capital2 shared
- Foresite CapitalVenture capital2 shared
- OrbiMedVenture capital2 shared
- Samsara BioCapitalVenture capital2 shared
- Andreessen HorowitzVenture capital1 shared
- Asahi Kasei Corporate Venture CapitalVenture capital1 shared
- Blackstone Life SciencesVenture capital1 shared
- Boxer CapitalVenture capital1 shared
- Deerfield Capital ManagementVenture capital1 shared
- Eli LillyVenture capital1 shared
Sectors
- Biotech7
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.